Great article about Abivax : what makes it a unique candidate to treat Covid-19

December 2, 2020

In addition to its exciting results in ulcerative colitis

In addition to its exciting results in ulcerative colitis, Abivax's ABX 464 has shown antiviral, anti-inflammatory and tissue repair properties in COVID-19 clinical trials.

Also to be discovered

BioMedTech

September 15, 2020

Abivax Turns Away Suitors as Lead Drug Starts Covid-19 Tests

Abivax, the French biotech embarking on tests of its lead experimental medicine for Covid-19, has turned away several suitors in recent months.

BioMedTech

July 31, 2020

MEDEOR, Truffle Capital's new BioMedTech Fund, qualified by institutional investors through the Tibi committee

Medeor is among the 24 new funds qualified by the committee of institutional investors set up following the Tibi report.

BioMedTech

June 2, 2020

Philippe Pouletty and Hartmut J. Ehrlich - ABIVAX - Covid-19 Quarantine

WCBS NewsRadio 880: CEO RADIO